AU2014368383B2 - Method of engineering multi-input signal sensitive T cell for immunotherapy - Google Patents

Method of engineering multi-input signal sensitive T cell for immunotherapy Download PDF

Info

Publication number
AU2014368383B2
AU2014368383B2 AU2014368383A AU2014368383A AU2014368383B2 AU 2014368383 B2 AU2014368383 B2 AU 2014368383B2 AU 2014368383 A AU2014368383 A AU 2014368383A AU 2014368383 A AU2014368383 A AU 2014368383A AU 2014368383 B2 AU2014368383 B2 AU 2014368383B2
Authority
AU
Australia
Prior art keywords
cell
domain
car
cells
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2014368383A
Other languages
English (en)
Other versions
AU2014368383A1 (en
Inventor
Claudia BERTONATI
Philippe Duchateau
Alexandre Juillerat
Laurent Poirot
Julien Valton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellectis SA
Original Assignee
Cellectis SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellectis SA filed Critical Cellectis SA
Publication of AU2014368383A1 publication Critical patent/AU2014368383A1/en
Application granted granted Critical
Publication of AU2014368383B2 publication Critical patent/AU2014368383B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AU2014368383A 2013-12-20 2014-12-19 Method of engineering multi-input signal sensitive T cell for immunotherapy Ceased AU2014368383B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201370806 2013-12-20
DKPA201370806 2013-12-20
PCT/EP2014/078876 WO2015092024A2 (en) 2013-12-20 2014-12-19 Method of engineering multi-input signal sensitive t cell for immunotherapy

Publications (2)

Publication Number Publication Date
AU2014368383A1 AU2014368383A1 (en) 2016-06-30
AU2014368383B2 true AU2014368383B2 (en) 2020-01-16

Family

ID=49884853

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014368383A Ceased AU2014368383B2 (en) 2013-12-20 2014-12-19 Method of engineering multi-input signal sensitive T cell for immunotherapy

Country Status (6)

Country Link
US (1) US10239948B2 (enExample)
EP (2) EP3808410A1 (enExample)
JP (1) JP2017504601A (enExample)
AU (1) AU2014368383B2 (enExample)
CA (1) CA2934436A1 (enExample)
WO (1) WO2015092024A2 (enExample)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2832569A1 (en) 2011-04-08 2012-10-11 Baylor College Of Medicine Reversing the effects of the tumor microenvironment using chimeric cytokine receptors
US9752113B2 (en) 2012-03-15 2017-09-05 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
US10689609B2 (en) 2012-03-15 2020-06-23 Flodesign Sonics, Inc. Acoustic bioreactor processes
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US9745548B2 (en) 2012-03-15 2017-08-29 Flodesign Sonics, Inc. Acoustic perfusion devices
US10322949B2 (en) 2012-03-15 2019-06-18 Flodesign Sonics, Inc. Transducer and reflector configurations for an acoustophoretic device
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US10737953B2 (en) 2012-04-20 2020-08-11 Flodesign Sonics, Inc. Acoustophoretic method for use in bioreactors
WO2014117121A1 (en) 2013-01-28 2014-07-31 St. Jude Children's Research Hospital, Inc. A chimeric receptor with nkg2d specificity for use in cell therapy against cancer and infectious disease
US9745569B2 (en) 2013-09-13 2017-08-29 Flodesign Sonics, Inc. System for generating high concentration factors for low cell density suspensions
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
US9944709B2 (en) 2014-03-19 2018-04-17 Cellectis CD123 specific chimeric antigen receptors for cancer immunotherapy
AU2015243849B2 (en) 2014-04-10 2020-12-17 Seattle Children's Hospital (dba Seattle Children's Research Institute) Transgene genetic tags and methods of use
CA2945620C (en) * 2014-04-14 2022-12-06 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
KR102211120B1 (ko) 2014-05-15 2021-02-03 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
US9744483B2 (en) 2014-07-02 2017-08-29 Flodesign Sonics, Inc. Large scale acoustic separation device
TWI805109B (zh) 2014-08-28 2023-06-11 美商奇諾治療有限公司 對cd19具專一性之抗體及嵌合抗原受體
IL301458A (en) 2014-12-24 2023-05-01 Autolus Ltd A cell that simultaneously expresses a chimeric antigen receptor (CAR) of 19CD and 22CD
WO2016120218A1 (en) 2015-01-26 2016-08-04 Cellectis ANTI-CLL1 SPECIFIC SINGLE-CHAIN CHIMERIC ANTIGEN RECEPTORS (scCARS) FOR CANCER IMMUNOTHERAPY
US11161907B2 (en) * 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
MX2017012939A (es) 2015-04-08 2018-05-22 Novartis Ag Terapias cd20, terapias cd22 y terapias de combinacion con una celula que expresa un receptor quimerico de antigeno (car) de cd19.
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
BR112017024757A2 (pt) 2015-05-18 2018-11-13 TCR2 Therapeutics Inc. composições e métodos para reprogramação de tcr utilizando proteínas de fusão
CA2990694A1 (en) 2015-07-08 2017-01-12 The Johns Hopkins University Marrow infiltrating lymphocytes (mils) as a source of t-cells for chimeric antigen receptor (car) therapy
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
AU2016302881B2 (en) 2015-08-03 2022-09-15 Bristol-Myers Squibb Company Monoclonal antibodies against BCMA
JP7162530B2 (ja) * 2015-08-07 2022-10-28 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞
MX2018008345A (es) * 2016-01-11 2018-12-06 Univ Leland Stanford Junior Proteínas quiméricas y métodos de inmunoterapia.
IL304088A (en) * 2016-01-11 2023-08-01 Univ Leland Stanford Junior Systems containing chimeric proteins and their uses for controlling gene expression
EP3405481B1 (en) 2016-01-21 2023-01-18 Pfizer Inc. Chimeric antigen receptors targeting epidermal growth factor receptor variant iii
CN109219618B (zh) 2016-01-21 2022-08-09 辉瑞大药厂 针对表皮生长因子受体变体iii和cd3的单特异性和双特异性抗体及其用途
EP3202783A1 (en) * 2016-02-02 2017-08-09 Ecole Polytechnique Fédérale de Lausanne (EPFL) Engineered antigen presenting cells and uses thereof
WO2017144630A1 (en) * 2016-02-26 2017-08-31 Cellectis Micelle based system nuclease encapsulation for in-vivo gene editing
CN107298715B (zh) 2016-04-15 2021-05-04 阿思科力(苏州)生物科技有限公司 Slit2D2-嵌合抗原受体及其应用
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
GB201609604D0 (en) * 2016-06-01 2016-07-13 Ucl Business Plc Cell
KR20190019121A (ko) 2016-06-17 2019-02-26 오사카 유니버시티 종양 내 정맥 형성 촉진제
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
MX2019003899A (es) 2016-10-07 2019-08-14 Tcr2 Therapeutics Inc Composiciones y metodos para reprogramacion de receptores de linfocitos t mediante el uso de proteinas de fusion.
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
WO2018073393A2 (en) 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3535295A1 (en) 2016-11-02 2019-09-11 EngMab Sàrl Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma
AU2017363311A1 (en) 2016-11-22 2019-06-13 TCR2 Therapeutics Inc. Compositions and methods for TCR reprogramming using fusion proteins
US11408005B2 (en) 2016-12-12 2022-08-09 Seattle Children's Hospital Chimeric transcription factor variants with augmented sensitivity to drug ligand induction of transgene expression in mammalian cells
WO2018182511A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
AU2018246378A1 (en) * 2017-03-31 2019-10-17 Cellectis Sa New universal chimeric antigen receptor T cells specific for CD22
EP3612568B8 (en) * 2017-04-18 2021-12-08 Autolus Limited Cell
CN110913871B (zh) 2017-05-17 2024-02-23 西雅图儿童医院（Dba西雅图儿童研究所） 生成哺乳动物t细胞活化诱导型合成启动子(syn+pro)以改善t细胞疗法
CA3067914A1 (en) 2017-06-30 2019-01-03 Cellectis Cellular immunotherapy for repetitive administration
GB201711470D0 (en) * 2017-07-17 2017-08-30 Univ Oxford Innovation Ltd Chimeric receptors
US20210130775A1 (en) * 2017-08-02 2021-05-06 Autolus Limited Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed
WO2019072824A1 (en) 2017-10-09 2019-04-18 Cellectis IMPROVED ANTI-CD123 CAR IN UNIVERSAL MODIFIED IMMUNE T LYMPHOCYTES
SG11202003907WA (en) 2017-12-14 2020-05-28 Flodesign Sonics Inc Acoustic transducer drive and controller
BR112020011893A2 (pt) * 2017-12-15 2020-11-24 The Board Of Trustees Of The Leland Stanford Junior University composições e métodos para inibir a exaustão de células t
CN111801348A (zh) 2018-02-09 2020-10-20 新加坡国立大学 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
CA3095757A1 (en) 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating glioblastomas
EP3773632A4 (en) 2018-04-06 2022-05-18 The Regents of The University of California METHODS OF TREATMENT OF EGFRVIII-EXPRESSING GLIOBLASTOMA
IL321548A (en) 2018-05-22 2025-08-01 Immunitybio Inc Recombinant NK cells expressing a chimeric antigen receptor (CAR) for epsilon-FC and uses thereof
WO2020028744A1 (en) * 2018-08-02 2020-02-06 Asimov, Inc. Universal chimeric receptors
SG11202100616VA (en) 2018-08-07 2021-03-30 Purdue Research Foundation Rejuvenation of car t cell
EP3844186A4 (en) 2018-08-29 2022-08-17 National University of Singapore METHOD OF SPECIFIC STIMULATION OF SURVIVAL AND EXPANSION OF GENETICALLY MODIFIED IMMUNE CELLS
EP3844180A4 (en) * 2018-08-31 2022-07-20 California Institute of Technology Synthetic protein circuits detecting signal transducer activity
CN112912727A (zh) * 2018-08-31 2021-06-04 因维克蒂斯股份有限公司 评估car功能性的方法
EP3850088A4 (en) 2018-09-07 2023-07-19 Beam Therapeutics, Inc. Compositions and methods for improving base editing
AU2019336245B2 (en) 2018-09-07 2026-02-26 Beam Therapeutics Inc. Compositions and methods for delivering a nucleobase editing system
MX2021005022A (es) 2018-11-01 2021-09-08 Juno Therapeutics Inc Receptores de antigenos quimericos especificos para el miembro d del grupo 5 de la clase c del receptor acoplado a proteina g (gprc5d).
US12109238B2 (en) 2018-11-06 2024-10-08 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells
IL277414B2 (en) * 2018-11-06 2025-04-01 Immunitybio Inc NK–92 cells with chimeric antigen receptor modification
EP3876956A4 (en) 2018-11-08 2022-12-28 The Regents of The University of California SYSTEMS AND METHODS FOR TARGETING CANCER CELLS
AU2019384145A1 (en) * 2018-11-20 2021-06-10 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell expressing therapeutic agent and uses thereof
CA3120563A1 (en) 2018-11-26 2020-06-04 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
CN114040977B (zh) 2019-01-31 2024-09-03 比姆医疗股份有限公司 非靶脱氨反应减低的核碱基编辑器和用于定性核碱基编辑器的测定
SG11202108346WA (en) 2019-02-13 2021-08-30 Beam Therapeutics Inc Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence
AU2020223314A1 (en) 2019-02-13 2021-08-12 Beam Therapeutics Inc. Compositions and methods for treating alpha-1 antitrypsin deficiency
GB201902277D0 (en) * 2019-02-19 2019-04-03 King S College London Therapeutic agents
JP7684691B2 (ja) * 2019-02-25 2025-05-28 国立大学法人東京科学大学 キメラ抗原受容体
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
US12479890B2 (en) 2019-04-26 2025-11-25 The University Of North Carolina At Chapel Hill Chimeric antigen receptor constructs and their use in CAR-T cells
CN115279398B (zh) 2019-09-27 2025-07-04 比姆医疗股份有限公司 治疗液态癌症的组合物和方法
KR20220104217A (ko) 2019-11-26 2022-07-26 노파르티스 아게 Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
AU2020403155A1 (en) * 2019-12-11 2022-06-30 Myeloid Therapeutics, Inc. Therapeutic cell compositions and methods for manufacture and uses thereof
WO2021131944A1 (ja) * 2019-12-27 2021-07-01 国立大学法人神戸大学 癌遺伝子治療薬
WO2022046755A1 (en) * 2020-08-28 2022-03-03 Innovative Cellular Therapeutics Holdings, Ltd. Fusion protein enhancing cell therapy
CN116635044A (zh) * 2020-08-28 2023-08-22 创新细胞治疗控股有限公司 融合蛋白增强细胞疗法
US12576151B2 (en) 2020-09-25 2026-03-17 Beam Therapeutics Inc. Fratricide resistant modified immune cells and methods of using the same
JP2024500847A (ja) 2020-12-18 2024-01-10 センチュリー セラピューティクス，インコーポレイテッド 適合可能な受容体特異性を有するキメラ抗原受容体システム
IL311570A (en) 2021-10-14 2024-05-01 Arsenal Biosciences Inc Immune cells with common expression chain and logic gate systems
EP4424714A4 (en) * 2021-10-29 2025-10-15 Shanghai Sinobay Biotechnology Co Ltd Condition-Controlled Splicable Chimeric Antigen Receptor Molecule and Its Use
US20250017960A1 (en) * 2021-11-15 2025-01-16 The Board Of Trustees Of The Leland Stanford Junior University Composition and method of valency controlled receptor systems for cell engineering and therapy
WO2024015383A1 (en) * 2022-07-12 2024-01-18 Northwestern University Engineered hypoxia biosensors and methods of using the same
CN120051298A (zh) 2022-08-05 2025-05-27 朱诺治疗学股份有限公司 Gprc5d和bcma特异性嵌合抗原受体
EP4573116A2 (en) * 2022-08-15 2025-06-25 The Regents Of The University Of California Multi-chain synthetic receptors for simultaneous ligand-induced transcriptional regulation and membrane-proximal signal transduction
KR20250084940A (ko) * 2022-09-30 2025-06-11 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 입양 t 세포 치료를 향상시키기 위한 조성물 및 방법
CN119306846A (zh) * 2023-07-14 2025-01-14 广州百吉生物制药有限公司 一种工程化免疫细胞及其制备和应用
AU2024336545A1 (en) * 2023-09-08 2026-04-16 Northwestern University Chimeric antigen receptors with card domains
WO2025076422A1 (en) * 2023-10-05 2025-04-10 The Regents Of The University Of California Regulated expression of card11-pik3r3 fusion protein
WO2025084881A1 (ko) * 2023-10-20 2025-04-24 주식회사 이온셀 Ct83 항원에 결합하는 car-t 세포 및 이의 용도

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
WO2002074981A2 (en) 2001-03-21 2002-09-26 Isis Innovation Ltd. Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
EP1778616A1 (en) 2004-08-09 2007-05-02 Cancer Research Technology Limited Alpha-ketoglutarates and their use as therapeutic agents
HUE025945T2 (en) * 2005-02-15 2016-07-28 Univ Duke Anti-CD19 antibodies and their applications in oncology
CN102796741A (zh) 2006-07-31 2012-11-28 脉管生物生长有限公司 多肽和其编码多核苷酸及它们在治疗缺血相关医学病症中的应用
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
US8822647B2 (en) * 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
ES2618632T3 (es) 2011-09-28 2017-06-21 Zera Intein Protein Solutions, S.L. Inteínas divididas y usos de éstas
EP3594245A1 (en) * 2012-02-13 2020-01-15 Seattle Children's Hospital d/b/a Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
US20130280220A1 (en) 2012-04-20 2013-10-24 Nabil Ahmed Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes
EP4541818A3 (en) * 2012-05-25 2025-07-23 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US20150017136A1 (en) * 2013-07-15 2015-01-15 Cellectis Methods for engineering allogeneic and highly active t cell for immunotherapy
CN103483452B (zh) * 2012-06-12 2021-08-13 上海细胞治疗集团有限公司 双信号独立的嵌合抗原受体及其用途
ES2714523T3 (es) * 2012-09-04 2019-05-28 Cellectis Receptor quimérico de antígenos multicatenario y usos del mismo
EP2970426B1 (en) * 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
TWI654206B (zh) * 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
CN107460201A (zh) 2013-05-08 2017-12-12 科济生物医药（上海）有限公司 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
RS63798B1 (sr) * 2013-05-13 2022-12-30 Cellectis Cd19 specifični himerni antigenski receptor i njegove primene
RU2725542C2 (ru) * 2013-05-13 2020-07-02 Селлектис Способы конструирования высокоактивных т-клеток для иммунотерапии
EP3027204B1 (en) * 2013-07-29 2022-01-05 2seventy bio, Inc. Multipartite signaling proteins and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANG SONNY O ET AL, "Conditional Activation of T Cells to Specifically Target c-Met under Hypoxia", MOLECULAR THERAPY, NATURE PUBLISHING GROUP, GB, (2009-05-01), vol. 17, no. Suppl.1, ISSN 1525-0016, pages S25 - S26 *
ANG SONNY O ET AL, "Conditional T-Cell Activation for Tumor Under Hypoxia", BLOOD, AMERICAN SOCIETY OF HEMATOLOGY, US, (2008-11-01), vol. 112, no. 11, ISSN 0006-4971, pages 1331 - 1332 *
Cooper, OMB#0704-0188, Grant# W81XWH-10-1-0765, September 2011 *

Also Published As

Publication number Publication date
US10239948B2 (en) 2019-03-26
AU2014368383A1 (en) 2016-06-30
WO2015092024A2 (en) 2015-06-25
WO2015092024A3 (en) 2015-08-13
JP2017504601A (ja) 2017-02-09
US20170073423A1 (en) 2017-03-16
CA2934436A1 (en) 2015-06-25
EP3808410A1 (en) 2021-04-21
EP3083691A2 (en) 2016-10-26

Similar Documents

Publication Publication Date Title
US10239948B2 (en) Method of engineering multi-input signal sensitive T cell for immunotherapy
JP7474281B2 (ja) リンパ球に形質導入を行うための方法及び組成物、並びにその制御された増加
AU2019201818B2 (en) CD19 specific chimeric antigen receptor and uses thereof
Guedan et al. Engineering and design of chimeric antigen receptors
KR102170533B1 (ko) 암 면역요법을 위한 cd33 특이적 키메라 항원 수용체들
AU2016313082B2 (en) Chimeric antigen receptors with integrated controllable functions
CN115058395B (zh) 嵌合抗原受体(car)、组合物及其使用方法
US20190135894A1 (en) COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHODS OF USE THEREOF
US20170296623A1 (en) INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN
CA3078735A1 (en) Compound chimeric antigen receptor (ccar) targeting multiple antigens, compositions and methods of use thereof
KR20170068539A (ko) Ｃａｒ―유도된 면역 세포들 활성의 조절 방법
KR20210045418A (ko) 크렙스 사이클을 조정하는 트랜스 대사 분자와 조합된 키메라 항원 수용체 폴리펩타이드 및 이의 치료적 용도
AU2015206040A1 (en) Chimeric antigen receptor using antigen recognition domains derived from cartilaginous fish
AU2015364245A1 (en) Chimeric antigen receptors and methods of use thereof
US20220348633A1 (en) COMPOUND CHIMERIC ANTIGEN RECEPTOR (cCAR) TARGETING MULTIPLE ANTIGENS, COMPOSITIONS AND METHOD OF USE THEREOF
Zhu Next Generation Receptors for the Enhanced Control of Cell-based Immunotherapies
JP7054181B2 (ja) キメラ抗原受容体
Chen Outsmarting and Outmuscling Cancer Cells for Next-Generation CAR-T Cell Therapies
HK40071469A (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
EA050303B1 (ru) Генетически сконструированная гемопоэтическая клетка, экспрессирующая глутамино-щавелевоуксусную трансаминазу и полипептид химерного рецептора, соответствующие фармацевтические композиции, способы ингибирования клеток и применения нуклеиновых кислот для получения указанной генетически сконструированной гемопоэтической клетки
BR112018069075B1 (pt) Métodos e composições para transduzir linfócitos e expansão regulada dos mesmos
HK1222679B (en) Cd19 specific chimeric antigen receptor and uses thereof
HK1208879B (en) Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired